Liraglutide Powder Cas No.204656-20-2

We specialise in the production of high-purity liraglutide active pharmaceutical ingredient (Liraglutide API, CAS 204656-20-2). Our products undergo a strictly controlled manufacturing process and rigorous quality validation via HPLC methodology. They exhibit exceptional stability and consistency, fully meeting the stringent standards required for pharmaceutical-grade APIs.

We are committed to meeting diverse client requirements, from research and development trials to large-scale commercial production. Striving to be your trusted partner, we provide stable, reliable, and high-quality liraglutide active pharmaceutical ingredients.

Liraglutide is classified as a glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic polypeptide with high homology to human GLP-1, enabling it to mimic its physiological functions. Its primary pharmacological actions pharmacological actions include glucose-dependent stimulation of insulin secretion, suppression of glucagon secretion, delayed gastric emptying, and central appetite suppression.

Liraglutide activates the GLP-1 receptors on pancreatic beta-cells, initiating intracellular signaling pathways that promote the synthesis and release of insulin when blood glucose levels are elevated. Concurrently, it acts on alpha-cells to inhibit glucagon secretion. A fatty acid side chain in its molecular structure allows reversible binding to albumin, significantly extending its half-life and enabling once-daily dosing. Furthermore, it acts on centers in the brain to increase satiety and reduce appetite.

As an active pharmaceutical ingredient (API), the core efficacy of Liraglutide lies in providing the therapeutic component for formulating medications aimed at glycemic control and weight management. Drugs based on its mechanism have demonstrated significant clinical benefits: effectively reducing blood glucose and glycated hemoglobin (HbA1c) levels in patients with type 2 diabetes, while also conferring additional advantages such as weight reduction, lowered systolic blood pressure, and improved lipid profiles. Cardiovascular outcome trials have shown protective effects against major adverse cardiovascular events cardiovascular events.

This product, as a high-standard API, is primarily used by downstream pharmaceutical manufacturers to produce approved prescription drugs, including:

Treatment of Type 2 Diabetes: For improving glycemic control in adults with type 2 diabetes.

Weight Management: For chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related comorbidity.

Hot Tags: liraglutide powder cas no.204656-20-2, China liraglutide powder cas no.204656-20-2 manufacturers, suppliers, factory, tranexamic powder